IL18 and prostate carcinoma: In this in vitro setting, we detected significant reduction in TC2R prostate cancer cell viability when IL-27 was used alone or co-administered with IL-18 relative to untreated control (Figure 1A; *, p < 0.05) and each single cytokine alone (#, p < 0.05).